About
Sexually Transmitted Infections Surveillance, 2024 (Provisional) provides the latest national data on trends for three nationally notifiable STIs: chlamydia, gonorrhea, and syphilis, including congenital syphilis.
Overview
The overall U.S. STI burden remains substantial, but signs of progress continue
In 2024, the combined total number of cases of chlamydia, gonorrhea, and syphilis declined 9% from 2023, down a third consecutive year. There were still more than 2.2 million reported STIs in 2024, and compared to a decade ago, overall cases are 13% higher; congenital syphilis is nearly 700% higher. Other key findings:
- Chlamydia cases declined for the second year in a row, down 8% since 2023.
- Gonorrhea cases declined for the third year in a row, down 10% since 2023.
- Congenital syphilis increased for the 12th year in a row, with nearly 4,000 reported cases in 2024. Primary and secondary syphilis cases declined for the second year in row, down 22% since 2023.
While the STI epidemic touches nearly every community, some geographic areas and populations may experience increases or decreases not reflected by the newest 2024 national data.
Highlights
Slides
Note: NNDSS STI case notification data presented in this slide deck, and the accompanying data files, are provisional as of August 14, 2025; therefore, case counts and rates may change when 2024 data are finalized.
Table
Trends in Reported Cases and Rates of Reported Cases for Nationally Notifiable Sexually Transmitted Infections, United States, 2020–2024
| Disease | Sex* | Cases | Percent Change | |||||
|---|---|---|---|---|---|---|---|---|
| 2020 | 2021 | 2022 | 2023 | 2024† | 5 Year | 1 Year | ||
| Total Syphilis‡ | Total | 133,965 | 176,744 | 207,273 | 209,249 | 190,242 | 42.0 | -9.1 |
| Congenital Syphilis§ | Total | 2,168 | 2,886 | 3,773 | 3,878 | 3,941 | 81.8 | 1.6 |
| Primary and Secondary Syphilis | Men | 33,646 | 41,349 | 44,309 | 39,188 | 29,575 | -12.1 | -24.5 |
| Women | 7,901 | 12,265 | 14,652 | 13,763 | 11,859 | 50.1 | -13.8 | |
| Total | 41,655 | 53,767 | 59,016 | 53,007 | 41,496 | -0.4 | -21.7 | |
| Early Non-Primary Non-Secondary Syphilis | Men | 35,165 | 40,979 | 44,143 | 40,486 | 33,401 | -5.0 | -17.5 |
| Women | 7,809 | 10,668 | 12,674 | 13,036 | 14,061 | 80.1 | 7.9 | |
| Total | 43,145 | 51,830 | 56,913 | 53,573 | 47,539 | 10.2 | -11.3 | |
| Unknown Duration or Late Syphilis | Men | 31,868 | 44,548 | 55,094 | 60,718 | 57,591 | 80.7 | -5.2 |
| Women | 14,959 | 23,474 | 32,347 | 37,996 | 39,540 | 164.3 | 4.1 | |
| Total | 46,997 | 68,261 | 87,571 | 98,791 | 97,266 | 107.0 | -1.5 | |
| Gonorrhea | Men | 385,551 | 410,388 | 390,548 | 378,428 | 341,667 | -11.4 | -9.7 |
| Women | 290,666 | 298,015 | 255,566 | 221,176 | 198,932 | -31.6 | -10.1 | |
| Total | 677,769 | 710,151 | 648,056 | 601,319 | 543,409 | -19.8 | -9.6 | |
| Chlamydia | Men | 548,676 | 587,473 | 601,205 | 610,445 | 564,489 | 2.9 | -7.5 |
| Women | 1,027,061 | 1,053,246 | 1,043,573 | 1,033,036 | 943,890 | -8.1 | -8.6 | |
| Total | 1,579,885 | 1,644,416 | 1,649,716 | 1,648,568 | 1,515,985 | -4.0 | -8.0 | |
| Combined Total of Total Syphilis, Gonorrhea, and Chlamydia | Total | 2,391,619 | 2,531,311 | 2,505,045 | 2,459,136 | 2,249,636 | -5.9 | -8.5 |
| Disease | Sex* | Rates per 100,000 Population | Percent Change | |||||
|---|---|---|---|---|---|---|---|---|
| 2020 | 2021 | 2022 | 2023 | 2024† | 5 Year | 1 Year | ||
| Total Syphilis‡ | Total | 40.4 | 53.3 | 62.2 | 62.5 | 55.9 | 38.4 | -10.6 |
| Congenital Syphilis§ | Total | 60.0 | 78.8 | 102.9 | 107.8 | 109.6 | 82.7 | 1.7 |
| Primary and Secondary Syphilis | Men | 20.5 | 25.2 | 26.8 | 23.6 | 17.6 | -14.1 | -25.4 |
| Women | 4.7 | 7.3 | 8.7 | 8.1 | 6.9 | 46.8 | -14.8 | |
| Total | 12.6 | 16.2 | 17.7 | 15.8 | 12.2 | -3.2 | -22.8 | |
| Early Non-Primary Non-Secondary Syphilis | Men | 21.4 | 24.9 | 26.7 | 24.4 | 19.8 | -7.5 | -18.9 |
| Women | 4.7 | 6.4 | 7.5 | 7.7 | 8.2 | 74.5 | 6.5 | |
| Total | 13.0 | 15.6 | 17.1 | 16.0 | 14.0 | 7.7 | -12.5 | |
| Unknown Duration or Late Syphilis | Men | 19.4 | 27.1 | 33.3 | 36.6 | 34.2 | 76.3 | -6.6 |
| Women | 8.9 | 14.0 | 19.3 | 22.5 | 23.0 | 158.4 | 2.2 | |
| Total | 14.2 | 20.6 | 26.3 | 29.5 | 28.6 | 101.4 | -3.1 | |
| Gonorrhea | Men | 234.8 | 249.7 | 236.3 | 228.3 | 203.0 | -13.5 | -11.1 |
| Women | 173.8 | 177.9 | 152.1 | 130.7 | 115.8 | -33.4 | -11.4 | |
| Total | 204.5 | 214.0 | 194.4 | 179.5 | 159.8 | -21.9 | -11.0 | |
| Chlamydia | Men | 334.2 | 357.4 | 363.7 | 368.3 | 335.3 | 0.3 | -9.0 |
| Women | 614.1 | 628.8 | 621.2 | 610.7 | 549.5 | -10.5 | -10.0 | |
| Total | 476.7 | 495.5 | 495.0 | 492.2 | 445.7 | -6.5 | -9.4 | |
| Combined Total of Total Syphilis, Gonorrhea, and Chlamydia | Total | 721.6 | 762.7 | 751.6 | 734.3 | 661.4 | -8.3 | -9.9 |
| * Total includes cases reported with missing information on sex. † Data are provisional as of August 14, 2025. ‡ Total includes cases of syphilis (all stages) and congenital syphilis. § Sex of infant is not reported. Rates are per 100,000 live births. NOTE: Cases and rates shown in this table include District of Columbia but exclude US territories. See Technical Notes for more information. This report includes data from years that coincide with the COVID-19 pandemic, which introduced uncertainty and difficulty in interpreting case data. See Impact of COVID-19 on STIs for more information. |
||||||||
Technical Notes
Surveillance and Data Science Branch
Division of STD Prevention
National Center for HIV, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Andre Berro, Darlene Davis, Nicole Gallaway, Reynaldo Grant, Jeremy Grey, Daniel Gore, LaZetta Grier, Alesia Harvey, Sammie Haskin, Robin Hennessy, David Jackson, Michelle Johnson Jones, Saugat Karki, Kristen Kreisel, Kevin O'Callaghan, Melissa Pagaoa, Alejandro Perez, Bianca Perri, Tracy Pondo, Matthew Pooser, R. Luke Shouse, Jamie Smimble, Elizabeth Torrone, Jane Yang, Elliane Yashar, Yan Yuan
Division of STD Prevention
Tranita Anderson, Laura Bachmann, Sherry Chen, Keith Davis, Daniel Johnson, Jennifer Ludovic, Nikki Mayes, Liana Narcisse, Puja Seth, Salina Smith, Bradley Stoner
National Center for HIV, Viral Hepatitis, STD, and TB Prevention
Homma Rafi, Rachel Wingard
Publication of this report would not have been possible without the contributions of the state, local, tribal, and territorial health departments, STI control programs, and public health laboratories that provided STI surveillance data to CDC.
All material contained in this report is in the public domain and may be used and reprinted without special permission; however, citation as to source is appreciated.
Centers for Disease Control and Prevention. Sexually Transmitted Infections Surveillance 2024 (Provisional). Atlanta: U.S. Department of Health and Human Services; 2025.
Nationally Notifiable Diseases Surveillance System (NNDSS) STI case notification data presented in this report are provisional as of August 14, 2025; therefore, case counts and rates may change when 2024 data are finalized.
- Because 2024 data are provisional, only national level trends are presented.
- National trends include cases reported among non-U.S. residents and exclude U.S. territories.
- As congenital syphilis cases may be diagnosed and reported years after birth, 2024 case counts will likely increase prior to data finalization.
- Provisional congenital syphilis case rates presented in this report were calculated using the most recent data available for live birth denominators (2023); all other provisional case rates were calculated using 2024 population denominators.
For additional data visualizations using the most current finalized data, please see
- 2023 STI Surveillance Report, available at: https://www.cdc.gov/sti-statistics/media/pdfs/2025/09/2023_STI_Surveillance_Report_FINAL_508.pdf
- NCHHSTP AtlasPlus, available at https://www.cdc.gov/nchhstp/about/atlasplus.html
For more information on the source and technical details of the data presented in this report, including interpretation of trends, please see:
- Technical Notes from the 2023 STI Surveillance Report, available at: https://www.cdc.gov/sti-statistics/media/pdfs/2025/09/2023_STI_Surveillance_Report_FINAL_508.pdf
- Impact of COVID-19 on STIs, available at: https://www.cdc.gov/sti-statistics/about/impact-of-covid-19.html